Membrane transporters in drug development and as determinants of precision medicine-Reference-Cited by-同舟云学术

Membrane transporters in drug development and as determinants of precision medicine

Published:2024-01-24 Issue:4 Volume:23 Page:255-280
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Galetin Aleksandra^ORCID,Brouwer Kim L. R.^ORCID,Tweedie Donald,Yoshida Kenta^ORCID,Sjöstedt Noora^ORCID,Aleksunes Lauren^ORCID,Chu Xiaoyan,Evers Raymond,Hafey Michael J.,Lai Yurong^ORCID,Matsson Pär^ORCID,Riselli Andrew^ORCID,Shen Hong,Sparreboom Alex,Varma Manthena V. S.,Yang Jia^ORCID,Yang Xinning,Yee Sook Wah^ORCID,Zamek-Gliszczynski Maciej J.,Zhang Lei^ORCID,Giacomini Kathleen M.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41573-023-00877-1.pdf

Reference254 articles.

1. Giacomini, K. M. et al. Membrane transporters in drug development. Nat. Rev. Drug. Discov. 9, 215–236 (2010). This is a seminal publication from the newly formed ITC that coalesced extensive discussions and output from the first ITC workshop, identified a subset of clinically relevant transporters and outlined decision trees that could be applied in translating in vitro experimental outcomes to likelihood of clinical findings resulting from drug–drug interactions; it formed the basis for regulatory recommendations for drug transporters in guidance documents.

2. Zamek-Gliszczynski, M. J. et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin. Pharmacol. Ther. 94, 64–79 (2013).

3. Zamek-Gliszczynski, M. J. et al. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clin. Pharmacol. Ther. 104, 890–899 (2018).

4. Chu, X. et al. Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the International Transporter Consortium. Clin. Pharmacol. Ther. 104, 836–864 (2018). This manuscript summarizes challenges and limitations of clinical probe drugs and emerging biomarkers for drug transporters to support clinical development of safe and effective therapeutics; workflows for identification and validation of novel endogenous biomarkers are proposed.

5. Chu, X. et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin. Pharmacol. Ther. 94, 126–141 (2013).

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The pH-dependence of efflux ratios determined with bidirectional transport assays across cellular monolayers;International Journal of Pharmaceutics: X;2024-12

2. Human enteroid monolayers as a potential alternative for Ussing chamber and Caco-2 monolayers to study passive permeability and drug efflux;European Journal of Pharmaceutical Sciences;2024-10

3. Advanced applications of Nanodiscs-based platforms for antibodies discovery;Biophysical Chemistry;2024-10

4. Drug transporters in drug disposition – highlights from the year 2023;Drug Metabolism Reviews;2024-09-11

5. Utility of Biomarker‐Informed Drug Interaction Evaluation in Drug Development and Regulatory Decision Making;Clinical Pharmacology & Therapeutics;2024-09-09